Institution
Yonsei University
Education•Seoul, South Korea•
About: Yonsei University is a education organization based out in Seoul, South Korea. It is known for research contribution in the topics: Population & Cancer. The organization has 50162 authors who have published 106172 publications receiving 2279044 citations. The organization is also known as: Yonsei.
Topics: Population, Cancer, Thin film, Breast cancer, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The incorporation of Zn(2+) dopants in tetrahedral sites leads to the successful magnetism tuning of spinel metal ferrite nanoparticles, which results in the largest MRI contrast effects reported to date and also huge hyperthermic effects.
Abstract: Doped up: The incorporation of Zn(2+) dopants in tetrahedral sites leads to the successful magnetism tuning of spinel metal ferrite nanoparticles (see picture). (Zn(0.4)Mn(0.6))Fe(2)O(4) nanoparticles exhibit the highest magnetization value among the metal ferrite nanoparticles. Such high magnetism results in the largest MRI contrast effects (r2=860 mm(-1) s(-1)) reported to date and also huge hyperthermic effects.
545 citations
••
TL;DR: It is shown that Atg5, which is known to function in autophagy, contributes to autophagic cell death by interacting with Fas-associated protein with death domain (FADD), and down-regulation of AtG5 expression in HeLa cells suppresses cell death and vacuole formation induced by IFN-γ.
542 citations
••
TL;DR: Dabrafenib plus trametinib is the first regimen demonstrated to have robust clinical activity in BRAF V600E-mutated anaplastic thyroid cancer and was well tolerated, representing a meaningful therapeutic advance for this orphan disease.
Abstract: Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E-mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. Methods In this phase II, open-label trial, patients with predefined BRAF V600E-mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death. The primary end point was investigator-assessed overall response rate. Secondary end points included duration of response, progression-free survival, overall survival, and safety. Results Sixteen patients with BRAF V600E-mutated anaplastic thyroid cancer were evaluable (median follow-up, 47 weeks; range, 4 to 120 weeks). All patients had received prior radiation treatment and/or surgery, and six had received prior systemic therapy. The confirmed overall response rate was 69% (11 of 16; 95% CI, 41% to 89%), with seven ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached as a result of a lack of events, with 12-month estimates of 90%, 79%, and 80%, respectively. The safety population was composed of 100 patients who were enrolled with seven rare tumor histologies. Common adverse events were fatigue (38%), pyrexia (37%), and nausea (35%). No new safety signals were detected. Conclusion Dabrafenib plus trametinib is the first regimen demonstrated to have robust clinical activity in BRAF V600E-mutated anaplastic thyroid cancer and was well tolerated. These findings represent a meaningful therapeutic advance for this orphan disease.
542 citations
••
TL;DR: Experimental results indicated that expanded SRTs (stationary phase) can be recommended while using the fungal and bacterial Cr-resistant isolates for removing chromium and nickel from industrial wastewater.
541 citations
••
TL;DR: The present paper reviews medicinal plants that have shown experimental or clinical antidiabetic activity and that have been used in traditional systems of medicine and natural products isolated from the medicinal plants and reported during 2001 to 2005.
Abstract: Currently available therapeutic options for non-insulin-dependent diabetes mellitus, such as dietary modification, oral hypoglycemics, and insulin, have limitations of their own. Many natural products and herbal medicines have been recommended for the treatment of diabetes. The present paper reviews medicinal plants that have shown experimental or clinical antidiabetic activity and that have been used in traditional systems of medicine; the review also covers natural products (active natural components and crude extracts) isolated from the medicinal plants and reported during 2001 to 2005. Many kinds of natural products, such as terpenoids, alkaloids, flavonoids, phenolics, and some others, have shown antidiabetic potential. Particularly, schulzeines A, B, and C, radicamines A and B, 2,5-imino-1,2,5-trideoxy-L-glucitol, beta-homofuconojirimycin, myrciacitrin IV, dehydrotrametenolic acid, corosolic acid (Glucosol), 4-(alpha-rhamnopyranosyl)ellagic acid, and 1,2,3,4,6-pentagalloylglucose have shown significant antidiabetic activities. Among active medicinal herbs, Momordica charantia L. (Cucurbitaceae), Pterocarpus marsupium Roxb. (Leguminoceae), and Trigonella foenum graecum L. (Leguminosae) have been reported as beneficial for treatment of type 2 diabetes.
540 citations
Authors
Showing all 50632 results
Name | H-index | Papers | Citations |
---|---|---|---|
Younan Xia | 216 | 943 | 175757 |
Peer Bork | 206 | 697 | 245427 |
Ralph Weissleder | 184 | 1160 | 142508 |
Hyun-Chul Kim | 176 | 4076 | 183227 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Yongsun Kim | 156 | 2588 | 145619 |
Jongmin Lee | 150 | 2257 | 134772 |
James M. Tiedje | 150 | 688 | 102287 |
Guanrong Chen | 141 | 1652 | 92218 |
Kazunori Kataoka | 138 | 908 | 70412 |
Herbert Y. Meltzer | 137 | 1148 | 81371 |
Peter M. Rothwell | 134 | 779 | 67382 |
Tae Jeong Kim | 132 | 1420 | 93959 |
Shih-Chang Lee | 128 | 787 | 61350 |
Ming-Hsuan Yang | 127 | 635 | 75091 |